Clinical Trials Logo

Advanced Cancer clinical trials

View clinical trials related to Advanced Cancer.

Filter by:

NCT ID: NCT04398875 Not yet recruiting - Advanced Cancer Clinical Trials

Adjunctive Effect of Acupuncture for Advanced Cancer Patients With Palliative Care: a Three-arm Randomized Trial

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

The proposed study aims to evaluate the adjunctive effect of MA with standard care (ASC) for relieving cancer-related symptoms in a collaborative model of palliative care compared to sham MA plus standard care (SSC) or standard care alone (SC).

NCT ID: NCT04385654 Not yet recruiting - Advanced Cancer Clinical Trials

Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma

Start date: June 2020
Phase: Phase 2
Study type: Interventional

This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of toripalimab combined with axitinib as neoadjuvant therapy for advanced/metastatic non-clear cell renal cell carcinoma

NCT ID: NCT04376931 Not yet recruiting - Advanced Cancer Clinical Trials

A Prospective Dose Finding Study of Iscador Infusion

Start date: December 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Prospective, dose-escalating mono-center open label dose-finding study without control group (3+3 design), including a follow-up on-treatment observation. In this study will be recruited 15 patients with a histologically or cytologically confirmed diagnosis of an advanced malignant disease during a therapy-free interval.Investigational drug:Iscador®P: fermented aqueous extract of mistletoe grown on pine tree (Viscum album L. subspecies austriacum (Wiesb.) Vollmann), licensed for subcutaneous (SC) application in Switzerland, Germany, Austria, Sweden, and South Korea in dosages up to 20 mg. The initial dose group of the study is set to 40 mg Iscador®P.

NCT ID: NCT04121039 Not yet recruiting - Advanced Cancer Clinical Trials

Study of the Apatinib Combine With POF Versus POF in Gastric Cancer

Start date: December 2019
Phase: Phase 2
Study type: Interventional

This study is a randomized, parallel control, multicenter,phase II study, comparing the efficacy and safety of apatinib plus POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) versus POF, in the first-line treatment for patients with advanced/metastatic gastric cancer.

NCT ID: NCT04089306 Not yet recruiting - Advanced Cancer Clinical Trials

Integration of Palliative Care in an Oncology and Hematology Unit

Start date: October 1, 2019
Phase:
Study type: Observational

The main goal of this study is to assess retrospectively the integration of Palliative Care in an oncology and hematology unit. The investigators will study the last six month of life on advanced cancer patients and retrieve data from their medical file to obtain criterias of quality of care and integration of palliative care in this population. Those criterias have been used before in other setting (Earle Criterias, ESMO Recommendations) and The investigators will compare our data to existing publications. They also hope to see if it is retrospectively possible to assess the probability of death using the Pronopall score. This will help them asses if aggressive end of life care could have been avoided using the Pronopall Score

NCT ID: NCT03645200 Not yet recruiting - Advanced Cancer Clinical Trials

Treatment of Carrying TP53 Harmful Mutations

Start date: July 1, 2019
Phase: Phase 1
Study type: Interventional

Assessment of the safety and tolerability of Fluzoparib combined with Apatinib in the treatment of advanced refractory solid tumors with TP53 harmful mutations.

NCT ID: NCT03554889 Not yet recruiting - Advanced Cancer Clinical Trials

Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells

Start date: August 1, 2018
Phase: Phase 1
Study type: Interventional

NK cells can persist and expand in vivo following adoptive transfer and may have a role in the treatment of late stage malignancies. NK also express an activating Fc receptor that mediates antibody-dependent cellular cytotoxicity (ADCC) and production of immune modulatory cytokines in response to antibody-coated targets. Nimotuzumab, an monoclonal antibody against EGFR (epidermal growth factor receptor), may enhance the ADCC effect of NK cell. This study will evaluate the safety of combination of nimotuzumab and NK Cell in treating advanced cancer patients. Blood samples will also be collected for research purposes.

NCT ID: NCT03518970 Not yet recruiting - Quality of Life Clinical Trials

Uncertainty in Illness in Palliative Care: an Intervention for Family Caregivers

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

Background: The increase of chronic diseases has reached an increase in the suffering of advanced diseases and an inability of health care systems to give access to the population that suffers them. In this context are people with advanced cancer who are in palliative care and the family caregivers. Uncertainty in illness in palliative care and quality of life are two concepts that are altered in the patient's family caregiver in palliative care. Objective: to examine the feasibility and acceptability of a nursing intervention to reduce the uncertainty in illness and improve the quality of life of family caregivers of patients with cancer in palliative care. Methodology: Phase II clinical trial, the ratio of recruitment, follow-up of participants as well as satisfaction with the intervention will be evaluated as primary outcomes. As secondary outcomes, the possible effect of the intervention on the uncertainty in illness and the quality of life of the family caregiver will be evaluated. This study will be carry out in a health care institution in Medellin-Colombia.

NCT ID: NCT03008109 Not yet recruiting - Advanced Cancer Clinical Trials

Endostar Plus EGFR-TKI(Epidermal Growth Factor Receptor—Tyrosine-Kinase Inhibitor) as a Treatment of EGFR Mutation-positive NSCLC

Start date: February 2017
Phase: Phase 3
Study type: Interventional

EGFR Tyrosine-Kinase Inhibitor monotherapy is widely used in treatment of patients with EGFR mutation-positive Non-small cell lung cancer(NSCLC), In despite of the benefit of PFS (progression-free survival) , the OS ( overall survival) is limited extended. This study is aim to observe the safety and efficacy of the combination of an anti-angiogenic drug recombinant human-endostatin with EGFR TKI ,to find out a new strategy which may further extend the PFS and OS with a tolerated toxicity.

NCT ID: NCT01313247 Not yet recruiting - Advanced Cancer Clinical Trials

Paracetamol for Cancer Pain

Start date: April 2011
Phase: Phase 4
Study type: Interventional

Randomised, double-blind placebo controlled cross-over trial Main goal: Optimize the medical pain treatment for patients with advanced cancer disease Study goal: Measure paracetamol's additional analgesic effect in a situation where the patient is concomitantly treated with oral opioids eqv. morphine > 100 mg/d.